Using Raman Spectroscopy to Diagnose Kidney Diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect serum and morning urine samples from patients diagnosed with IgA nephropathy, membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis at Qianfoshan Hospital in Shandong Province. The samples will be analyzed using Raman spectroscopy to obtain spectral data, which will be processed to identify chemical compounds associated with these kidney diseases. The study will establish calibration curves to quantitatively analyze the concentration of specific analytes in the samples, potentially leading to improved diagnostic methods for these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 18 years or older;
2. Patients diagnosed with IgA nephropathy, idiopathic membranous nephrop, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy;
3. Patients who have not received hormone and/or immunosup therapy before the renal biopsy;

Exclusion Criteria:

1. Presence of factors causing secondary membranous nephropathy: such as autoimmune diseases (systemic lupus erythematosus),/infections (viral hepatitis), drugs or toxins, etc.;
2. Severe infection: clinical manifestations such as fever, cough and sputum, throat, abdominal pain, diarrhea, boils and other skin and soft tissue infections, with white blood cell count in blood routine exceeding the normal range (10×09/L);
3. Severe cardiovascular disease: including chronic heart failure of grade 3 or above and various arrhythmias;
4. Infect diseases: active phase of various types of hepatitis, AIDS, syphilis, etc.;
5. Evidence of tumor: already diagnosed with a certain tumor or manifestations, tumor markers, etc. indicating the possibility of a tumor;
6. Patients with incomplete data or missed diagnosis.

Where it's running

• Shandong Second Medical University. No.7166 Baotong West Street, Weifang, Shandong, 261053, China.
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Zunsong Wang, Dr
• Email: wzsong3@163.com
• Phone: 15966608835

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Everest001: a medicine for certain kidney diseases to see if it helps adults

  This study tests EVER001 in adults with FSGS, MCD, or IgA nephropathy to see if it can help reduce protein in the urine and improve kidney function.

  Recruiting at 2 sites Phase 2 Everest Medicines (China) Co.,Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07614477

• JADE101 in IgA Nephropathy (phase 3, blinded)

  This phase 3 study tests whether JADE101 helps adults with IgA nephropathy more than a placebo.

  Recruiting at 4 sites Phase 3 Jade Biosciences, Inc. · Arvada, Colorado and 3 other locations · NCT07902817

• Rituximab plus Cyclosporine for Primary Membranous Nephropathy

  This study tests whether adding Cyclosporine to Rituximab helps people with primary membranous nephropathy achieve remission of heavy protein in the urine faster.

  Recruiting Phase 2/3 Peking University First Hospital · Beijing · NCT07861204

• Umbilical Cord Mesenchymal Stem Cells for Diabetic Kidney Disease

  This study tests whether injecting human umbilical cord mesenchymal stem cells can help people with diabetic nephropathy by reducing kidney inflammation and damage.

  Recruiting Phase 1 Tongji Hospital · Wuhan · NCT07822152

• Personalized IgA Nephropathy treatment guided by Gd-IgA1 monitoring

  This study tests whether regularly checking a biomarker called Gd-IgA1 to guide treatment with Nefecon or telitacicept helps people with IgA nephropathy or related nephritis respond better.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07822100

• Lactoferrin Supplement in Diabetic Kidney Disease

  Scientists test whether adding lactoferrin helps people with diabetic nephropathy who also have moderately to severely increased urinary albumin.

  Recruiting Phase 2 Ain Shams University · Cairo · NCT07764991

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.